Battle of the biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma

Lehrich, Brandon M.; Zhang, Josephine; Monga, Satdarshan P.; Dhanasekaran, Renumathy

doi:10.1016/j.jhep.2023.11.030

Cited by 7 publications

(3 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, there is a pressing need to identify effective biomarkers to guide selection of NSCLC patients that might derive survival benefit from chemoIO treatment. Due to the invasive and time-consuming nature of histopathological evaluation which is currently a standard disease monitoring approach, identifying a novel blood-based biomarker that is non-invasive and easily accessible is of great clinical significance ( 21 ). In contrast with tumor tissues, the immune cells in the peripheral blood would provide a far more convenient sample source for patient selection and might offer a more comprehensive immune landscape of the whole tumor since they are circulated systemically ( 22 , 23 ).…”

Section: Discussionmentioning

confidence: 99%

Peripheral CD4+ T cells correlate with response and survival in patients with advanced non-small cell lung cancer receiving chemo-immunotherapy

Yang,

Li,

Zeng

2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundThe aim of the present study was to explore the potential of peripheral immune cells in predicting the response and prognosis of patients with advanced non-small cell lung cancer (NSCLC) receiving anti-PD-1 immunotherapy and platinum-based chemotherapy.Participants and MethodsWe utilized flow cytometry to examine the levels and dynamics of blood immune cells in 79 advanced NSCLC patients treated with the chemoimmunotherapy between December 2019 and January 2022. The pre- and post-treatment blood samples were collected within 3 days prior to the initiation of the first and third cycle of combination treatment, respectively. Progression-free survival (PFS) and overall survival (OS) analyses were conducted using Kaplan-Meier method and Cox regression models.ResultsThe pre-treatment CD4+/Total T cells ratio was significantly higher in responders than non-responders (P < 0.05). The levels of pre-treatment total lymphocytes (P = 0.012), total B lymphocytes (P = 0.025), and NK cells (P = 0.022), and post-treatment NK cells (P = 0.011) and NKT cells (P = 0.035) were significantly associated with OS. Post-treatment CD8+/Total T cells ratio was positively correlated with OS (P = 0.038). In multivariate analysis, post-treatment NK cells and post-treatment CD4+CD8+/Total T cells ratio were negatively associated with OS (hazard ratio [HR] = 10.30, P = 0.038) and PFS (HR = 1.95, P = 0.022), respectively. Notably, significantly positive correlations were observed between CD4+/Total T cells ratio and prognosis both before and after treatment (P < 0.05).ConclusionTo summarize, our finding reveals that high CD4+/total T cells ratio was associated with favorable response and prognosis, highlighting its potential as a predictive biomarker to guide the selection of likely responders to platinum and anti-PD-1 combination therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Peripheral CD4+ T cells correlate with response and survival in patients with advanced non-small cell lung cancer receiving chemo-immunotherapy

Yang,

Li,

Zeng

2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“… 16 Overall, these classification systems illustrate how tumor genetics drive both tumoral heterogeneity and specific tumor microenvironments, which may be differentially susceptible to various systemic agents, and thus, may require tailored treatment options for patients informed by tissue and/or liquid biopsy. 17 …”

Section: Genetic Heterogeneity and Immunologic Landscapementioning

confidence: 99%

“…This may be aided by tissue or liquid biopsy for key drivers of HCC tumorigenesis. 17 However, an improved understanding of which genetic drivers influence the immune microenvironment resistant to ICI response is warranted for screening, along with needing an expanded arsenal of drugs targeting these underlying pathways to be used in conjunction with ICIs.…”

Section: Current Treatment Modalities and Patient Selectionmentioning

confidence: 99%

Lipid Nanovesicle Platforms for Hepatocellular Carcinoma Precision Medicine Therapeutics: Progress and Perspectives

Lehrich,

Delgado

2024

Organogenesis

Self Cite

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality globally. HCC is highly heterogenous with diverse etiologies leading to different driver mutations potentiating unique tumor immune microenvironments. Current therapeutic options, including immune checkpoint inhibitors and combinations, have achieved limited objective response rates for the majority of patients. Thus, a precision medicine approach is needed to tailor specific treatment options for molecular subsets of HCC patients. Lipid nanovesicle platforms, either liposome- (synthetic) or extracellular vesicle (natural)-derived present are improved drug delivery vehicles which may be modified to contain specific cargos for targeting specific tumor sites, with a natural affinity for liver with limited toxicity. This mini-review provides updates on the applications of novel lipid nanovesicle-based therapeutics for HCC precision medicine and the challenges associated with translating this therapeutic subclass from preclinical models to the clinic.

show abstract

Advances and Prospects in Liquid Biopsy Techniques for Malignant Tumor Diagnosis and Surveillance

Zhang,

Li,

Zhao

et al. 2024

Small

View full text Add to dashboard Cite

Liquid biopsy technology provides invaluable support for the early diagnosis of tumors and surveillance of disease course by detecting tumor‐related biomarkers in bodily fluids. Currently, liquid biopsy techniques are mainly divided into two categories: biomarker and label‐free. Biomarker liquid biopsy techniques utilize specific antibodies or probes to identify and isolate target cells, exosomes, or molecules, and these techniques are widely used in clinical practice. However, they have certain limitations including dependence on tumor markers, alterations in cell biological properties, and high cost. In contrast, label‐free liquid biopsy techniques directly utilize physical or chemical properties of cells, exosomes, or molecules for detection and isolation. These techniques have the advantage of not needing labeling, not impacting downstream analysis, and low detection cost. However, most are still in the research stage and not yet mature. This review first discusses recent advances in liquid biopsy techniques for early tumor diagnosis and disease surveillance. Several current techniques are described in detail. These techniques exploit differences in biomarkers, size, density, deformability, electrical properties, and chemical composition in tumor components to achieve highly sensitive tumor component identification and separation. Finally, the current research progress is summarized and the future research directions of the field are discussed.

show abstract

Battle of the biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma

Cited by 7 publications

References 133 publications

Peripheral CD4+ T cells correlate with response and survival in patients with advanced non-small cell lung cancer receiving chemo-immunotherapy

Peripheral CD4+ T cells correlate with response and survival in patients with advanced non-small cell lung cancer receiving chemo-immunotherapy

Lipid Nanovesicle Platforms for Hepatocellular Carcinoma Precision Medicine Therapeutics: Progress and Perspectives

Advances and Prospects in Liquid Biopsy Techniques for Malignant Tumor Diagnosis and Surveillance

Contact Info

Product

Resources

About